1
|
Ghosh S, Khandelia T, Mahadevan A, Panigrahi P, Kumar P, Mandal R, Boruah D, Venkataramani S, Patel BK. Photo-Induced Generation of Oxygenated Quaternary Centers via EnT Enabled Singlet O 2 Addition to C3-Maleimidated Quinoxaline: A Reagent-Less Approach. Chemistry 2024:e202400219. [PMID: 38717037 DOI: 10.1002/chem.202400219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Indexed: 06/15/2024]
Abstract
Demonstrated here is an external photo-sensitizer-free (auto-sensitized) singlet oxygen-enabled solvent-dependent tertiary hydroxylation and aryl-alkyl spiro-etherification of C3-maleimidated quinoxalines. Such "reagent-less" photo-oxygenation at Csp3-H and etherification involving Csp3-H/Csp2-H are unparalleled. Possibly, the highly π-conjugated N-H tautomer allows the substrate to get excited by irradiation, and subsequently, it attains the triplet state via ISC. This excited triplet-state sensitized molecule then transfers its energy to a triplet-state oxygen (3O2) generating reactive singlet oxygen (1O2) for hydroxylation and spirocyclization depending on the solvent used. In HFIP, the generated alkoxy radical accepts a proton via HAT giving hydroxylated product. In contrast, in an aprotic PhCl it underwent a radical addition at the ortho-position of the C2 aryl to provide spiro-ether. An unprecedented orthogonal spiro-etherification was observed via the displacement of o-substitutents for ortho (-OEt, -OMe, -F, -Cl, -Br) substituted substrates. The order of ipso substitution follows the trend -OMe>-OEt>-F>-H>-Cl>-Br. Both these oxygenation reactions can be carried out with nearly equal ease using direct sunlight without the requirement of any elaborate reaction setup. Demonstration of large-scale synthesis and a few interesting transformations have also been realized. Furthermore, several insightful control experiments and quantum chemical computations were performed to unravel the mechanism.
Collapse
Affiliation(s)
- Subhendu Ghosh
- Department of chemistry, Indian Institute of Technology Guwahati, Guwahati, 781039, India
| | - Tamanna Khandelia
- Department of chemistry, Indian Institute of Technology Guwahati, Guwahati, 781039, India
| | - Anjali Mahadevan
- Department of chemistry, Indian Institute of Science Education and Research Mohali, Manauli, Punjab, 140306, India
| | - Pritishree Panigrahi
- Department of chemistry, Indian Institute of Technology Guwahati, Guwahati, 781039, India
| | - Piyush Kumar
- Department of chemistry, Indian Institute of Science Education and Research Mohali, Manauli, Punjab, 140306, India
| | - Raju Mandal
- Department of chemistry, Indian Institute of Technology Guwahati, Guwahati, 781039, India
| | - Deepjyoti Boruah
- Department of chemistry, Indian Institute of Technology Guwahati, Guwahati, 781039, India
| | - Sugumar Venkataramani
- Department of chemistry, Indian Institute of Science Education and Research Mohali, Manauli, Punjab, 140306, India
| | - Bhisma K Patel
- Department of chemistry, Indian Institute of Technology Guwahati, Guwahati, 781039, India
| |
Collapse
|
2
|
Przybylski R, Eberly LM, Alexander ME, Bezzerides VJ, DeWitt ES, Dionne A, Mah DY, Triedman JK, Walsh EP, O'Leary ET. Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. J Cardiovasc Electrophysiol 2023; 34:2545-2551. [PMID: 37846208 PMCID: PMC10841442 DOI: 10.1111/jce.16095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Revised: 09/02/2023] [Accepted: 09/25/2023] [Indexed: 10/18/2023]
Abstract
INTRODUCTION The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD). Data are sparse regarding their use for the same purpose in adults with CHD and in adolescent patients with anatomically normal hearts and we sought to describe the use of class IC drugs in this population and identify factors associated with decreased likelihood of success. METHODS Single center retrospective cohort study of patients who received oral flecainide or propafenone for medical cardioversion of AF or IART from 2000 to 2022. The unit of analysis was each episode of AF/IART. We performed a time-to-sinus rhythm analysis using a Cox proportional hazards model clustering on the patient to identify factors associated with increased likelihood of success. RESULTS We identified 45 episodes involving 41 patients. As only episodes of AF were successfully cardioverted with medical therapy, episodes of IART were excluded from our analyses. Use of flecainide was the only factor associated with increased likelihood of success. There was a statistically insignificant trend toward decreased likelihood of success in patients with CHD. CONCLUSIONS Flecainide was more effective than propafenone. We did not detect a difference in rate of conversion to sinus rhythm between patients with and without CHD and were likely underpowered to do so, however, there was a trend toward decreased likelihood of success in patients with CHD. That said, medical therapy was effective in >50% of patients with CHD with AF.
Collapse
Affiliation(s)
- Robert Przybylski
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Logan M Eberly
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Mark E Alexander
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Vassilios J Bezzerides
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Elizabeth S DeWitt
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Audrey Dionne
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Douglas Y Mah
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - John K Triedman
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Edward P Walsh
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Edward T O'Leary
- Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA
| |
Collapse
|
3
|
Verma K, Lahariya AK, Dubey S, Verma AK, Das A, Schneider KA, Bharti PK. An integrated virtual screening and drug repurposing strategy for the discovery of new antimalarial drugs against Plasmodium falciparum phosphatidylinositol 3-kinase. J Cell Biochem 2021; 122:1326-1336. [PMID: 33998049 DOI: 10.1002/jcb.29954] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 04/28/2021] [Accepted: 05/03/2021] [Indexed: 11/10/2022]
Abstract
The emergence and spread of drug resistance in Plasmodium falciparum, the parasite causing the most severe form of human malaria, is a major threat to malaria control and elimination programs around the globe. With P. falciparum having evolved widespread resistance against a number of previously widely used drugs, currently, artemisinin (ART) and its derivatives are the cornerstones of first-line treatments of uncomplicated malaria. However, growing incidences of ART failure reflect the spread of ART-resistant P. falciparum strains. Despite current efforts to understand the primary cause of ART resistance due to mutations in the Kelch 13 gene (PfK13), the mechanism underlying ART resistance is still not completely unclear and no feasible strategies to counteract the causes and thereby restoring the efficiency of ART have been developed. We use a polypharmacology approach to identify potential drugs that can be used for the novel purpose (target). Of note, we have designed a multimodal stratagem to identify approved drugs with a potential antimalarial activity using computational drug reprofiling. Our investigations suggest that oxetacaine, simvastatin, repaglinide, aclidinium, propafenone, and lovastatin could be repurposed for malaria control and prevention.
Collapse
Affiliation(s)
- Kanika Verma
- Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, India
| | - Ayush K Lahariya
- Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, India
| | - Shivangee Dubey
- Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, India
| | - Anil K Verma
- Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, India
| | - Aparup Das
- Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, India
| | | | - Praveen K Bharti
- Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, India
| |
Collapse
|
4
|
Xu RA, Luo S, Lin Q, Shao Y, Chen C, Ye X. Inhibitory effect of propafenone on vortioxetine metabolism in vitro and in vivo. ARAB J CHEM 2021. [DOI: 10.1016/j.arabjc.2021.103136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
5
|
Doki K, Shirayama Y, Sekiguchi Y, Aonuma K, Kohda Y, Ieda M, Homma M. Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10. Pharmacogenomics 2020; 21:1279-1288. [PMID: 33203295 DOI: 10.2217/pgs-2020-0105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: The study aims to investigate the clinical implication of nonfunctional poor metabolizer (PM) alleles and intermediate metabolizer (IM) alleles of CYP2D6, including the CYP2D6*10 allele which shows substrate-dependent decrease in enzymatic activity, in antiarrhythmic therapy using propafenone. Materials & methods: We examined serum propafenone concentrations and metabolic ratio, which was expressed as serum concentrations of propafenone to 5-hydroxypropafenone, in 66 Japanese patients with tachyarrhythmias. Results: The peak propafenone concentration and metabolic ratio in CYP2D6 PM allele carriers were higher than those in extensive metabolizer (EM)/EM, EM/IM and IM/IM genotype groups. Conclusion: Results suggest that CYP2D6 PM alleles affect peak propafenone concentration, but the CYP2D6 IM allele CYP2D6*10 has no clinical implication in propafenone dosing.
Collapse
Affiliation(s)
- Kosuke Doki
- Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305 8575, Japan
| | - Yuki Shirayama
- Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305 8575, Japan
| | - Yukio Sekiguchi
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305 8575, Japan
| | - Kazutaka Aonuma
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305 8575, Japan
| | - Yukinao Kohda
- Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305 8575, Japan
| | - Masaki Ieda
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305 8575, Japan
| | - Masato Homma
- Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305 8575, Japan
| |
Collapse
|
6
|
Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring. Eur J Clin Pharmacol 2018; 74:1273-1279. [DOI: 10.1007/s00228-018-2541-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Accepted: 08/08/2018] [Indexed: 10/28/2022]
|
7
|
Zeljković I, Bulj N, Kolačević M, Čabrilo V, Brkljačić DD, Manola Š. Failure of Intracardiac Pacing After Fatal Propafenone Overdose: A Case Report. J Emerg Med 2018; 54:e65-e68. [PMID: 29336990 DOI: 10.1016/j.jemermed.2017.12.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 11/04/2017] [Accepted: 12/01/2017] [Indexed: 06/07/2023]
Abstract
BACKGROUND Propafenone is a sodium-channel blocker, class IC antiarrhythmic drug, frequently used to manage supraventricular dysrhythmias, especially atrial fibrillation. We report a self mono-intoxication with propafenone. CASE REPORT A 68-year-old woman presented with a decreased level of consciousness, hypotension, and electrocardiogram showing QRS widening with atrial asystole and extreme bradycardia < 20 beats/min. After initial stabilization with transcutaneous pacing, laboratory findings detected normal electrolyte ranges and metabolic acidosis, and her medical history revealed availability of propafenone due to paroxysmal atrial fibrillation and depressive syndrome, which led to the suspicion of intoxication. Despite intravenous sodium bicarbonate, calcium, norepinephrine, and aggressive fluid replacement (10% glucose with insulin), hemodynamic stability was not achieved. Temporary intracardiac pacing was implanted. However, even with multiple electrode positions, effective capture could not be achieved. At that time, transcutaneous pacing was also ineffective. Consequently, the patient died in refractory asystole due to complete myocardial nonexcitability. The concentration of 5270 ng/mL of propafenone was found in the blood at autopsy, using gas spectrometry-mass chromatography. It is the third highest reported propafenone lethal concentration and the first case in which the myocardial nonexcitability refractory to intracardiac pacing was seen despite normal electrode position in the right ventricle, with failure to achieve the patient's hemodynamic stability. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Emergency physicians should be aware of possible propafenone ingestion causing toxicity, which is probably more frequent than previously described, especially because propafenone is widely available due to its use in managing atrial fibrillation, the most common arrhythmia nowadays.
Collapse
Affiliation(s)
- Ivan Zeljković
- Department of Cardiology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
| | - Nikola Bulj
- Department of Cardiology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
| | - Matea Kolačević
- Unit of Clinical Pharmacology and Toxicology, Department of Internal Medicine, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
| | - Vedran Čabrilo
- Department of Emergency Medicine, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
| | - Diana Delić Brkljačić
- Department of Cardiology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
| | - Šime Manola
- Department of Cardiology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
| |
Collapse
|
8
|
Cardiac sodium channel antagonism - Translation of preclinical in vitro assays to clinical QRS prolongation. J Pharmacol Toxicol Methods 2017; 89:9-18. [PMID: 29042254 DOI: 10.1016/j.vascn.2017.10.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 08/31/2017] [Accepted: 10/09/2017] [Indexed: 12/19/2022]
Abstract
INTRODUCTION Cardiac sodium channel antagonists have historically been used to treat cardiac arrhythmias by preventing the reentry of the electrical impulse that could occur following myocardial damage. However, clinical studies have highlighted a significant increase in mortality associated with such treatment. Cardiac sodium channel antagonist activity is now seen as an off-target pharmacology that should be mitigated during the drug development process. The aim of this study was to examine the correlation between in vitro/ex vivo assays that are routinely used to measure Nav1.5 activity and determine the translatability of the individual assays to QRS prolongation in the clinic. METHODS A set of clinical compounds with known Nav1.5 activity was profiled in several in vitro/ex vivo assays (binding, membrane potential, patch clamp and the Langendorff isolated heart). Clinical data comprising compound exposure levels and changes in QRS interval were obtained from the literature. Sensitivity/specificity analysis was performed with respect to the clinical outcome. RESULTS The in vitro assays showed utility in predicting QRS prolongation in the clinic. Optimal thresholds were defined for each assay (binding: IC20; membrane potential: IC10; patch clamp: IC20) and sensitivity (69-88%) and specificity (53-84%) values were shown to be similar between assay formats. DISCUSSION The data provide clear statistical insight into the translatability of Nav1.5 antagonism data generated in vitro to potential clinical outcomes. These results improve our ability to understand the liability posed by such activity in novel development compounds at an early stage.
Collapse
|
9
|
Highly sensitive UHPLC–MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N -depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. J Pharm Biomed Anal 2017; 142:328-336. [DOI: 10.1016/j.jpba.2017.04.046] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Revised: 04/25/2017] [Accepted: 04/28/2017] [Indexed: 11/20/2022]
|
10
|
Patel H, Ghoghari A, Bhatt C, Shah S, Jha A, Desai N, Srinivas NR. A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-
depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. Biomed Chromatogr 2017; 31. [DOI: 10.1002/bmc.3967] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 02/17/2017] [Accepted: 03/02/2017] [Indexed: 11/06/2022]
Affiliation(s)
- Harilal Patel
- Zydus Research Centre; Bioanalytical Laboratory; Ahmedabad India
- Department of Chemistry; St Xavier's College (Autonomous); Ahmedabad India
| | - Ashok Ghoghari
- Zydus Research Centre; Bioanalytical Laboratory; Ahmedabad India
| | | | - Shaival Shah
- Zydus Research Centre; Bioanalytical Laboratory; Ahmedabad India
| | - Anilkumar Jha
- Zydus Research Centre; Bioanalytical Laboratory; Ahmedabad India
| | - Nirmal Desai
- Department of Chemistry; St Xavier's College (Autonomous); Ahmedabad India
| | | |
Collapse
|
11
|
Abstract
OBJECTIVE: To describe propafenone-induced liver injury. DESIGN: Retrospective case report. SETTING: Referred care in a large tertiary care center. Laboratory tests were performed at the auxiliary site and the tertiary care center. PATIENT: A 71-year-old woman with atrial fibrillation developed elevations of greater than two times the upper limit of normal in alkaline phosphatase (ALK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyltransferase (GGT) after initiation of propafenone therapy. INTERVENTIONS: Studies included serial measurements of ALK, ALT, AST, and GGT. RESULTS: The patient developed elevations of greater than two times the upper limit of normal in ALK, ALT, and AST, one month after initiating propafenone therapy. The propafenone dose was decreased from 900 to 675 mg/d and, ten days later, the ALK, ALT, and AST were decreased slightly, but still above the upper limit of normal. One month later, serum transaminases had returned to baseline, but propafenone therapy was discontinued because of recurrent atrial fibrillation, persistent elevation in ALK, and elevation in GGT. Two months after discontinuing propafenone, serum aminotransaminase and ALK concentrations had normalized and GGT had decreased and remained only slightly elevated. CONCLUSIONS: The occurrence of liver injury secondary to propafenone therapy is rare. Reported cases appear to be secondary to hepatocellular injury, cholestasis, or a combination of the two. In this case, the pattern demonstrated by elevations in liver enzymes may be classified as acute cholestatic liver injury. Because the reported incidence is 0.1–0.2 percent and there are no known fatalities secondary to propafenone liver injury, routine monitoring of liver function tests in all patients receiving propafenone cannot be recommended at this time. Baseline liver function tests prior to initiating propafenone therapy with follow-up laboratory studies one month later are recommended in patients with known liver dysfunction. If elevations are noted, a reduction in dose may result in lower liver enzyme concentrations, although discontinuation of therapy may be required in some cases.
Collapse
Affiliation(s)
- S A Spinler
- Philadelphia College of Pharmacy and Science, PA 19104
| | | | | |
Collapse
|
12
|
Stoschitzky K, Stoschitzky G, Lercher P, Brussee H, Lamprecht G, Lindner W. Propafenone shows class Ic and class II antiarrhythmic effects. Europace 2015; 18:568-71. [DOI: 10.1093/europace/euv195] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Accepted: 05/08/2015] [Indexed: 11/14/2022] Open
|
13
|
Pan L, Qian Y, Cheng M, Gu P, He Y, Xu X, Ding L. Pharmacokinetics of propafenone hydrochloride sustained-release capsules in male beagle dogs. Acta Pharm Sin B 2015; 5:74-8. [PMID: 26579428 PMCID: PMC4629124 DOI: 10.1016/j.apsb.2014.11.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Revised: 10/11/2014] [Accepted: 11/14/2014] [Indexed: 11/19/2022] Open
Abstract
This paper describes the development and validation of a liquid chromatography-mass spectrometric assay for propafenone and its application to a pharmacokinetic study of propafenone administered as a new propafenone hydrochloride sustained-release capsule (SR-test), as an instant-release tablet (IR-reference) and as the market leader sustained-release capsule (Rythmol, SR-reference) in male beagle dogs (n=8). In Study A comparing SR-test with IR-reference in a crossover design T max and t 1/2 of propafenone for SR-test were significantly higher than those for IR-reference while C max and AUC were lower demonstrating the sustained release properties of the new formulation. In Study B comparing SR-test with SR-reference the observed C max and AUC of propafenone for SR-test (124.5±140.0 ng/mL and 612.0±699.2 ng·h/mL, respectively) were higher than for SR-reference (78.52±72.92 ng/mL and 423.6±431.6 ng·h/mL, respectively) although the differences were not significant. Overall, the new formulation has as good if not better sustained release characteristics to the market leader formulation.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Li Ding
- Corresponding author. Tel./fax: +86 25 83271485.
| |
Collapse
|
14
|
β-Blocking Properties of Propafenone in Extensive Oxidisers: A Study on Heart Rate Behaviour during Holter Monitoring. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/bf03259424] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Boriarti G, Strocchi E, Capucci A, Boschi S, Marchesini B, Ambrosioni E, Magnani B. Relationships Between Debrisoquine Hydroxylation and Propafenone Pharmacokinetics. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/bf03258249] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
|
17
|
Marasanapalle VP, Boinpally RR, Zhu H(J, Grill A, Tang F. Correlation between the systemic clearance of drugs and their food effects in humans. Drug Dev Ind Pharm 2011; 37:1311-7. [DOI: 10.3109/03639045.2011.571697] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
18
|
Ovaska H, Ludman A, Spencer EP, Wood DM, Jones AL, Dargan PI. Propafenone poisoning--a case report with plasma propafenone concentrations. J Med Toxicol 2010; 6:37-40. [PMID: 20373066 PMCID: PMC3550440 DOI: 10.1007/s13181-010-0037-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Propafenone is an anti-arrhythmic drug used in the management of supraventricular and ventricular arrhythmias. It is metabolised through cytochrome P450 2D6 pathways; the major metabolites possess anti-arrhythmic activity. The cytochrome P450 CYP2D6 is coded by more than 70 alleles resulting in great genetic polymorphism of CYP2D6 isoenzymes, and up to 7% of Caucasian population are poor metabolisers. This case report describes a patient with severe overdose of propafenone who presented with coma, seizures and cardiotoxicity. The patient was managed with intravenous glucagon, hypertonic sodium bicarbonate, hypertonic saline and inotropic support. The propafenone and its 5-hydroxypropafenone (5-OHP) metabolite were measured by high-performance liquid chromatography with ultraviolet detection (no assay was available at the time to measure N-despropyl propafenone concentrations). Toxicological screen showed propafenone concentrations at a maximum of 1.26 mg/L at 9-10 h post-presentation, falling to 0.25 mg/L at 27-28 h post-presentation. No propafenone metabolite 5-OHP was detected in any sample analysed. No antidepressant or analgesic drugs were detected in toxicological screen. Propafenone overdose has been reported to be associated with features of severe cardiovascular and CNS toxicity. Aggressive treatment, meticulous monitoring and supportive care was associated with a good outcome in this case.
Collapse
Affiliation(s)
- Hanna Ovaska
- />Clinical Toxicology Service, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
| | | | - Edgar P. Spencer
- />Medical Toxicology Laboratory, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
| | - David M. Wood
- />Clinical Toxicology Service, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London, UK
- />Medical Toxicology Office, 2nd Floor, Bermondsey Wing, Guy’s Hospital, Great Maze Pond, London, SE1 9RT UK
| | | | - Paul I. Dargan
- />Clinical Toxicology Service, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London, UK
| |
Collapse
|
19
|
Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41:89-295. [PMID: 19514967 DOI: 10.1080/03602530902843483] [Citation(s) in RCA: 502] [Impact Index Per Article: 33.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Pharmacogenetics is the study of how interindividual variations in the DNA sequence of specific genes affect drug response. This article highlights current pharmacogenetic knowledge on important human drug-metabolizing cytochrome P450s (CYPs) to understand the large interindividual variability in drug clearance and responses in clinical practice. The human CYP superfamily contains 57 functional genes and 58 pseudogenes, with members of the 1, 2, and 3 families playing an important role in the metabolism of therapeutic drugs, other xenobiotics, and some endogenous compounds. Polymorphisms in the CYP family may have had the most impact on the fate of therapeutic drugs. CYP2D6, 2C19, and 2C9 polymorphisms account for the most frequent variations in phase I metabolism of drugs, since almost 80% of drugs in use today are metabolized by these enzymes. Approximately 5-14% of Caucasians, 0-5% Africans, and 0-1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant enzyme that demonstrates multiple genetic variants with a potentially functional impact on the efficacy and adverse effects of drugs that are mainly eliminated by this enzyme. Studies into the CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and *3 alleles. Extensive polymorphism also occurs in other CYP genes, such as CYP1A1, 2A6, 2A13, 2C8, 3A4, and 3A5. Since several of these CYPs (e.g., CYP1A1 and 1A2) play a role in the bioactivation of many procarcinogens, polymorphisms of these enzymes may contribute to the variable susceptibility to carcinogenesis. The distribution of the common variant alleles of CYP genes varies among different ethnic populations. Pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and currently available drugs. Further studies are warranted to explore the gene-dose, gene-concentration, and gene-response relationships for these important drug-metabolizing CYPs.
Collapse
Affiliation(s)
- Shu-Feng Zhou
- School of Health Sciences, RMIT University, Bundoora, Victoria, Australia.
| | | | | |
Collapse
|
20
|
Rehnqvist N, Ericsson CG, Eriksson S, Olsson G, Svensson G. Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. ACTA MEDICA SCANDINAVICA 2009; 216:525-30. [PMID: 6395642 DOI: 10.1111/j.0954-6820.1984.tb05041.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Propafenone, a new class I antiarrhythmic drug, given as a bolus injection followed by oral medication, or lidocaine were given to 20 consecutive patients admitted with chest pain suggesting acute myocardial infarction and showing high grades, i.e. multiform, pairs or R-on-T premature ventricular complexes or short runs of ventricular tachycardia. Before institution of therapy the mean number (+/- 1 SD) of premature ventricular contractions (PVCs) per hour was 169 +/- 123 in the lidocaine group and 324 +/- 440 in the propafenone group. During the next 24 hours lidocaine reduced the numbers of PVCs by 73% and propafenone by 75%. The mean number (+/- 1 SD) of 5-minute periods with high grade PVCs was 4.3 +/- 2.9 in the lidocaine group and 5.8 +/- 4.5 in the propafenone group. During therapy this number was equally reduced in both groups to 2.4. One patient in the lidocaine group developed ventricular fibrillation and three patients in the propafenone group were excluded because of increasing numbers of PVCs. One patient in the propafenone group showed a torsade-de-pointes ventricular tachycardia.
Collapse
|
21
|
De Clercq D, van Loon G, Tavernier R, Verbesselt R, Deprez P. Use of propafenone for conversion of chronic atrial fibrillation in horses. Am J Vet Res 2009; 70:223-7. [PMID: 19231955 DOI: 10.2460/ajvr.70.2.223] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To investigate effects of IV administration of propafenone for naturally occurring and experimentally induced chronic atrial fibrillation in horses. ANIMALS 2 horses with naturally occurring atrial fibrillation and 4 horses with pacing-induced atrial fibrillation. PROCEDURES Horses received a bolus of propafenone (2 mg/kg, IV over 15 minutes). If atrial fibrillation persisted after 20 minutes, a continuous infusion of propafenone (7 microg/kg/min) was given for 120 minutes. Before, during, and after treatment, plasma propafenone concentrations, hematologic and serum biochemical values, and electolyte concentrations analyses were determined and clinical signs were monitored. Surface ECGs were recorded. If propafenone treatment failed, quinidine sulfate was administered. RESULTS Bolus and continuous infusion induced minimal adverse effects. During the 15-minute bolus administration, a slight increase in heart rate was observed and horses appeared more sensitive to external stimuli. Throughout treatment, no significant changes were observed in respiratory rate, QRS or corrected QT duration, or results of hematologic analyses. Although a significant increase in F-wave interval and atrial fibrillation cycle length was observed and plasma propafenone concentrations (569 to 1,268 ng/mL) reached the human therapeutic range (64 to 1,044 ng/mL), none of the horses cardioverted to sinus rhythm. Sinus rhythm could be restored in all horses via standard oral administration of quinidine. CONCLUSIONS AND CLINICAL RELEVANCE A slow IV bolus of 2 mg of propafenone/kg followed by a continuous infusion of 7 microg/kg/min over 2 hours was not an effective treatment for chronic atrial fibrillation in horses.
Collapse
Affiliation(s)
- Dominique De Clercq
- Department of Large Animal Internal Medicine, Ghent University, Salisburylaan 133, B-9820, Merelbeke, Belgium
| | | | | | | | | |
Collapse
|
22
|
DINH HA, MURPHY MARVINL, BAKER BONNIEJ, DE SOYZA NEIL. Propafenone: A New Anti arrhythmic for Treatment of Chronic Ventricular Arrhythmias. ACTA ACUST UNITED AC 2008. [DOI: 10.1111/j.1540-8167.1986.tb01732.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
|
24
|
SALERNO DAVIDM. Part III: Class IC Antiarrhythmic Drugs-A Review of Their Pharmacokinetics, Electrophysiology, Efficacy, and Toxicity*. ACTA ACUST UNITED AC 2008. [DOI: 10.1111/j.1540-8167.1987.tb01435.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
25
|
|
26
|
|
27
|
Gareri P, Fazio PD, Gallelli L, Fazio SD, Davoli A, Seminara G, Cotroneo A, Sarro GD. Venlafaxine–Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation. Ann Pharmacother 2008; 42:434-8. [PMID: 18303146 DOI: 10.1345/aph.1k405] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Objective: To report a case of visual hallucinations and psychomotor agitation probably induced by an interaction between venlafaxine and propafenone. Case Summary: An 85-year-old woman was admitted for evaluation of a mood disorder on March 20, 2006. Her general practitioner had prescribed sertraline for treatment, which had started about 6 months earlier. The patient's medical history included hypertension, supraventricular tachycardia, chronic bronchitis, and arthritis, for which she received ramipril, ticlopidine, torsemide, theophylline, acetaminophen, and triazolam. The patient had also received propafenone 150 mg every 12 hours for 3 years. Results of biochemical tests were normal; however, a computed tomography (CT) scan of the brain showed signs of cortical atrophy. Sertraline was discontinued after a few days because of its reduced effectiveness and was replaced with extended-re lease venlafaxine 75 mg/day. No other changes to the patient's drug therapy were made. Four weeks later, because of the persistence of psychiatric disturbance, the venlafaxine dosage was increased to 150 mg/day. Ten days later the patient returned to our observation due to the onset of visual hallucinations lasting about 2 hours, especially at night, and psychomotor agitation. Venlafaxine was discontinued, with a complete remission of hallucinations and psychomotor agitation in about 4 days. The Naranjo probability scale indicated a probable relationship between venlafaxine and the patient's symptoms. Citalopram was started one month later for the persistence of mood disorders, with no adverse effects. Discussion: A CT scan documented signs of cortical atrophy in our patient's brain but excluded vascular brain injury, while clinical evaluation and anamnesis excluded a relationship between hallucinations and cortical atrophy. Genetic and pharmacologic factors may be involved in venlafaxine-induced adverse effects. Venlafaxine is metabolized primarily by CYP2D6 and is a substrate of P-glycoprotein. Propafenone, a known substrate and inhibitor of both CYP2D6 and P-glycoprotein, could therefore be involved in venlafaxine-induced hallucinations through the increase of venlafaxine plasma concentrations. Conclusions: To prevent the onset of clinical disturbances during venlafaxine treatment, we suggest careful evaluation of concomitant treatment with CYP2D6 or P-glycoprotein inhibitors (eg, propafenone) and, when possible, venlafaxine serum concentration monitoring.
Collapse
Affiliation(s)
- Pietro Gareri
- Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, Operative Unit Elderly Health Care, Catanzaro, Italy
| | - Pasquale De Fazio
- Clinical Psychiatric Unit, Chair of Psychiatry, Department of Experimental and Clinical Medicine, School of Medicine, University Magna Graecia of Catanzaro, Mater Domini University Hospital
| | - Luca Gallelli
- Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital
| | | | | | - Giuseppe Seminara
- Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital
| | | | - Giovambattista De Sarro
- Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital
| |
Collapse
|
28
|
Mörike K, Kivistö KT, Schaeffeler E, Jägle C, Igel S, Drescher S, Fux R, Marx C, Hofmann U, Engel C, Wagner F, Delabar U, Meisner C, Bail D, Böhm JO, Gleiter CH, Ziemer G, Rein JG, Hellberg KD, Eichelbaum M, Schwab M. Propafenone for the Prevention of Atrial Tachyarrhythmias After Cardiac Surgery: A Randomized, Double-blind Placebo-controlled Trial. Clin Pharmacol Ther 2008; 84:104-10. [DOI: 10.1038/sj.clpt.6100473] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Abstract
Despite advances in treatment, atrial fibrillation (AF) remains the most common arrhythmia in humans. Antiarrhythmic drug therapy continues to be a cornerstone of AF treatment, even in light of emerging non-pharmacologic therapies. Conventional antiarrhythmic drugs target cardiac ion channels and are often associated with modest AF suppression and the risk of ventricular proarrhythmia. Ongoing drug development has focused on targeting atrial-specific ion channels as well as novel non-ionic targets. Targeting non-ionic mechanisms may also provide new drugs directed towards the underlying mechanisms responsible for AF and possibly greater antiarrhythmic potency. Agents that act against these new targets may offer improved safety and efficacy in AF treatment.
Collapse
Affiliation(s)
- Deepak Bhakta
- Indiana University School of Medicine, Krannert Institute of Cardiology, 1800 N. Capitol Avenue, Indianapolis, IN 46202, USA.
| | | |
Collapse
|
30
|
Edrich T, Wang SY, Wang GK. State-dependent block of human cardiac hNav1.5 sodium channels by propafenone. J Membr Biol 2007; 207:35-43. [PMID: 16463141 DOI: 10.1007/s00232-005-0801-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2005] [Revised: 10/15/2005] [Indexed: 10/25/2022]
Abstract
State-dependent blockade of human cardiac hNav1.5 sodium channels by propafenone was studied using whole-cell patch clamp techniques. Both a direct investigation using cells with inactivation-deficient sodium channels and an algorithmic approach used on cells with wild-type channels revealed a rapid binding of propafenone to the open state. This occurs approximately 4000 and 700 times faster than the binding to the resting and inactivated state, respectively. An established mathematical "gating" model was modified to represent the experimental data.
Collapse
Affiliation(s)
- T Edrich
- Cellular Electrophysiology Laboratory, Department of Anesthesia, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
| | | | | |
Collapse
|
31
|
Triola BR, Kowey PR. Antiarrhythmic drug therapy. CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE 2006; 8:362-70. [PMID: 16939674 DOI: 10.1007/s11936-006-0040-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The use of antiarrhythmic drugs can be challenging to physicians. They are effective in treating various types of arrhythmias, yet their potential to cause adverse events, in particularly proarrhythmia, can be intimidating. When the decision to use antiarrhythmic therapy has been made, physicians are confronted with several issues: choosing the right drug, preventing complications, and selecting the setting in which the drug is to be given (in-hospital vs outpatient). In determining the best antiarrhythmic agent for each patient, one should have a basic understanding of their mechanisms of action and indications. Once this decision has been made, attention turns to avoiding complications and assessing for efficacy. Clinicians should be aware of the common drug interactions of each antiarrhythmic agent and avoid these whenever possible. In addition, patients need meticulous follow-up, including serial electrocardiograms and assessment for cardiovascular side effects. For several of the antiarrhythmic drugs, this can be accomplished in the outpatient setting in appropriate patients.
Collapse
Affiliation(s)
- Brian R Triola
- 558 Medical Office Building East, 100 Lancaster Avenue, Lankenau Hospital, Wynnewood, PA 19096, USA.
| | | |
Collapse
|
32
|
Hauser TH, Pinto DS, Josephson ME, Zimetbaum P. Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. Am J Cardiol 2004; 93:1173-6. [PMID: 15110217 DOI: 10.1016/j.amjcard.2004.01.051] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2003] [Revised: 01/12/2004] [Accepted: 01/12/2004] [Indexed: 10/26/2022]
Abstract
Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not. Three hundred thirty-nine patients were evaluated during drug loading with amiodarone or class 1C agents, and it was found that recurrent arrhythmia was common, usually not persistent, and frequently asymptomatic. Recurrent arrhythmia was not more common with amiodarone.
Collapse
Affiliation(s)
- Thomas H Hauser
- Cardiovascular Division, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA.
| | | | | | | |
Collapse
|
33
|
Abstract
Most antiarrhythmic drugs fulfil the formal requirements for rational use of therapeutic drug monitoring, as they show highly variable plasma concentration profiles at a given dose and a direct concentration-effect relationship. Therapeutic ranges for antiarrhythmic drugs are, however, often very poorly defined. Effective drug concentrations are based on small studies or studies not designed to establish a therapeutic range, with varying dosage regimens and unstandardised sampling procedures. There are large numbers of nonresponders and considerable overlap between therapeutic and toxic concentrations. Furthermore, no study has ever shown that therapeutic drug monitoring makes a significant difference in clinical outcome. Therapeutic concentration ranges for antiarrhythmic drugs as they exist today can give an overall impression about the drug concentrations required in the majority of patients. They may also be helpful for dosage adjustment in patients with renal or hepatic failure or in patients with possible toxicological or compliance problems. Their use in optimising individual antiarrhythmic therapy, however, is very limited.
Collapse
Affiliation(s)
- Gesche Jürgens
- Department of Clinical Pharmacology, Copenhagen University Hospital, Copenhagen, Denmark.
| | | | | |
Collapse
|
34
|
Palette C, Maroun N, Gaulier JM, Priolet B, Lachatre G, Bedos JP, Advenier C, Thérond P. Intoxication fatale par la propafénone : à propos d’un cas documenté par des dosages sanguins. Therapie 2003; 58:384-6; discussion 387. [PMID: 14679683 DOI: 10.2515/therapie:2003062] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
35
|
Abstract
Despite the emergence of several forms of nonpharmacologic therapy for cardiac arrhythmias, antiarrhythmic drugs continue to play an important role in the management of patients with this common clinical problem. The key to the proper use of antiarrhythmic drugs is a thorough knowledge of their mode of action and pharmacology. The pharmacology of antiarrhythmic drugs is particularly important because patients with cardiac arrhythmias frequently have multiorgan disease, which may influence the metabolism and elimination of antiarrhythmic drugs. The accumulation of toxic amounts of these agents can lead to dire effects including, but not limited to, ventricular proarrhythmia and malignant bradycardia. The goals of pharmacologic therapy of cardiac arrhythmia are to provide the maximum benefit in terms of arrhythmia suppression while maintaining patient safety. To accomplish these goals, a knowledge of the pharmacology of several antiarrhythmic drugs is mandatory.
Collapse
Affiliation(s)
- P R Kowey
- Division of Cardiology, Lankenau Hospital and Medical Research Center, Wynnewood, PA, USA
| | | | | | | |
Collapse
|
36
|
Fonck K, Haenebalcke C, Hemeryck A, Belpaire F, Jordaens L, Calle P, Buylaert W. ECG changes and plasma concentrations of propafenone and its metabolites in a case of severe poisoning. JOURNAL OF TOXICOLOGY. CLINICAL TOXICOLOGY 1998; 36:247-51. [PMID: 9656983 DOI: 10.3109/15563659809028948] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
CASE REPORT Propafenone is a class IC antiarrhythmic agent metabolized into two major metabolites, 5-hydroxypropafenone and N-depropylpropafenone. The potency of 5-hydroxypropafenone to block fast sodium channels is comparable to that of its parent. We report the positive correlation between plasma concentrations and electrocardiographic changes in a patient with severe oral self-poisoning. Serial ECG changes were measured and plasma concentrations were determined by high-performance liquid chromatography. The initial plasma concentrations of propafenone were in the toxic range and correlated with the widening of the QRS-complex. The slow decline in concentration during this first phase might relate to saturation of the isoenzyme CYP2D6. The half-life of propafenone, calculated from the second phase, was approximately 3 hours, defining the patient as a fast metabolizer. The initial concentrations of the metabolite N-depropylpropafenone were surprisingly higher than those of 5-hydroxypropafenone which may also be due to saturation of CYP2D6.
Collapse
Affiliation(s)
- K Fonck
- University Hospital of Ghent, Belgium
| | | | | | | | | | | | | |
Collapse
|
37
|
de Gaitani CM, Lanchote VL, Bonato PS. Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1998; 708:177-83. [PMID: 9653960 DOI: 10.1016/s0378-4347(97)00652-x] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We present a method for the enantioselective analysis of propafenone in human plasma for application in clinical pharmacokinetic studies. Propafenone enantiomers were resolved on a 10-microm Chiralcel OD-R column (250 x 4.6 mm I.D.) after solid-phase extraction using disposable solid-phase extraction tubes (RP-18). The mobile phase used for the resolution of propafenone enantiomers and the internal standard propranolol was 0.25 M sodium perchlorate (pH 4.0)-acetonitrile (60:40, v/v), at a flow-rate of 0.7 ml/min. The method showed a mean recovery of 99.9% for (S)-propafenone and 100.5% for (R)-propafenone, and the coefficients of variation obtained in the precision and accuracy study were below 10%. The proposed method presented quantitation limits of 25 ng/ml and was linear up to a concentration of 5000 ng/ml of each enantiomer.
Collapse
Affiliation(s)
- C M de Gaitani
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto-USP, Ribeirão Preto CEP, Brazil
| | | | | |
Collapse
|
38
|
Faber TS, Zehender M, Krahnefeld O, Daisenberger K, Meinertz T, Just H. Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 1997; 29:561-7. [PMID: 9060894 DOI: 10.1016/s0735-1097(96)00555-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVES The proarrhythmic risk of class I antiarrhythmic agents in combination with myocardial ischemia is mainly the result of their effects on ventricular repolarization. This study was designed to evaluate the effect of class Ic antiarrhythmic agents on QT dispersion during myocardial ischemia. BACKGROUND QT interval dispersion on the 12-lead electrocardiogram (ECG) has been suggested as a noninvasive marker of inhomogeneous ventricular repolarization and susceptibility to ventricular arrhythmias. METHODS In a randomized, double-blind study, 98 patients undergoing percutaneous transluminal coronary angioplasty (PTCA) were pretreated with propafenone or placebo. QT dispersion was defined as a maximal minus minimal QT interval on the 12-lead ECG before and after PTCA. The power of the study to detect clinically meaningful differences in QT dispersion was 0.75, and a twofold increase in QT dispersion in the propafenone group compared with the placebo group was considered clinically relevant. RESULTS The QT and corrected QT (QTc) intervals increased significantly during occlusion of the left anterior descending coronary artery (LAD) (9% and 11%, respectively, p < 0.05), whereas occlusion of the circumflex and right coronary arteries had no effect. QTc dispersion increased significantly in the propafenone group during ischemia (+52%, p = 0.002, vs. +23%, p = 0.15). The most considerable effect on QT dispersion was observed during LAD occlusion and ischemia of the anterior wall (+74%, p = 0.025). Corrected JT dispersion (+57%, p = 0.017, vs. +24%, p = 0.23) and the QT dispersion ratio (+1.6%, p = 0.031, vs. 0.9%, p = 0.34) showed similar effects. Plasma levels of propafenone (522 +/- 165 micrograms/liter) did not influence the results. CONCLUSIONS During myocardial ischemia, particularly during LAD occlusion, propafenone results in a significant increase in QT dispersion. The results indicate that QT interval prolongation and enhanced QT dispersion reflect inhomogeneous ventricular repolarization generated by the ischemic anterior wall of the myocardium. These observations may demonstrate a clinically important interaction between myocardial ischemia, repolarization variables and propafenone.
Collapse
Affiliation(s)
- T S Faber
- Universitätsklinik Freiburg, Abteilung für Kardiologie und Angiologie, Germany
| | | | | | | | | | | |
Collapse
|
39
|
Abstract
Propafenone hydrochloride, a class 1C antiarrhythmic agent, combines sodium channel-blocking effects with beta-blocking capacities and a weak calcium antagonism. The drug exerts marked electrophysiologic effects on accessory atrioventricular pathways. In patients with atrioventricular nodal reentry tachycardia, propafenone is able to block conduction in the fast conducting pathway. In addition, propafenone is very effective in young patients with supraventricular tachycardia based on enhanced abnormal automaticity. In pediatric patients, left ventricular performance remains unimpaired. Proarrhythmic events have been noted in children only occasionally. In accordance with the electrophysiologic profile, intravenous and oral propafenone is an effective agent for treatment of supraventricular tachycardia based on a reentry mechanism and due to abnormal automaticity (i.e., supraventricular tachycardia based on an accessory atrioventricular pathway, atrioventricular nodal reentry tachycardia, junctional ectopic tachycardia, and atrial ectopic tachycardia). In children with ventricular dysrhythmias, efficacy seems to be related to the underlying cardiac diagnosis. Propafenone is well tolerated in the majority of young patients. Incidence of proarrhythmic events seems to be lower with propafenone than with other class 1C agents. However, the risk of these serious adverse events should be taken into account when therapy with propafenone is considered, particularly in patients with structural heart disease.
Collapse
Affiliation(s)
- T Paul
- Children's Hospital, Hannover Medical School, Germany
| | | |
Collapse
|
40
|
Abstract
Propafenone is an infrequently used class IC antiarrhythmic drug. We report our experience with a patient who overdosed with propafenone and developed coma, seizures, bradycardia, hypotension, and conduction delay. The clinical manifestations and management of this patient are discussed in light of the known pharmacology of propafenone and compared with the limited number of cases that appear in the literature.
Collapse
Affiliation(s)
- W Kerns
- Department of Emergency Medicine, Carolinas Medical Center, Charlotte, North Carolina
| | | | | |
Collapse
|
41
|
Puigdemont A, Ramis J, Guitart R, Arboix M. Species scaling of propafenone disposition and concentration--time relationships among eight mammalian species. J Pharm Sci 1993; 82:1126-9. [PMID: 8289126 DOI: 10.1002/jps.2600821112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Usually, smaller mammals have higher clearances per unit body mass than do larger mammalian species. When clearance and other pharmacokinetic parameters are correlated with internal physiological processes, species tend to dispose of drugs at a similar pace. The first application of this concept is pharmacokinetic time, expressed with different units: Kallynochron, Apolysichron, Dienetichron, and Syndesichron. The present work describes pharmacokinetic time in these units from data obtained with propafenone in eight animal species: mouse, rat, rabbit, dog, sheep, human, cow, and horse. Additionally, volume of distribution (Vdss = 6.5 B0.94) and clearance (CL = 0.17 B0.86) were correlated to body weight (B). Different units of pharmacokinetic time were evaluated with an Akaike Information Criterion test, and the Syndesichron was the unit that provided the best superimposition for the concentration-time plot for all animal species. It can be inferred that all mammalian species eliminated half of the dose from their bodies in 4759 Syndesichrons.
Collapse
Affiliation(s)
- A Puigdemont
- Department of Pharmacology, School of Veterinary, Autonomous University of Barcelona, Bellaterra, Spain
| | | | | | | |
Collapse
|
42
|
Leboeuf J, Basiez M, Massingham R. Electrophysiological effects of Org 7797 in the closed-chest anaesthetized dog. Br J Pharmacol 1993; 110:23-8. [PMID: 8220882 PMCID: PMC2176014 DOI: 10.1111/j.1476-5381.1993.tb13766.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
1. The intravenous electrophysiological effects of a new antifibrillatory agent, Org 7797, were studied in closed chest anaesthetized dogs. Effects of fast sodium and slow calcium-mediated action potentials were also examined in guinea-pig isolated papillary muscle. 2. The major effects of a known antifibrillatory dose of Org 7797 (0.5 mg kg-1) were a protracted slowing of AV nodal conduction (for at least 20 min) and prolongation of the AV nodal functional refractory period. Conduction in the atria and His-Purkinje system (reflected by the St-A and HV intervals) were not significantly modified whilst ventricular conduction (reflected by the QRS interval) and the ventricular functional refractory period were only transiently prolonged. No other electrophysiological changes were seen. 3. A higher dose of Org 7797 (1.5 mg kg-1) slowed conduction at all levels of the myocardium (as evidenced by increases in the St-A, AH, HV and QRS intervals), slightly shortened cardiac repolarization (as assessed from JTc) and decreased Wenckebach rate. Atrial refractory periods were increased whereas effects on ventricular refractory periods were modest. 4. Neither heart rate nor sinus node recovery time were modified by either dose of Org 7797. 5. Org 7797, at a concentration (20 microM) which reduced Vmax of fast sodium-mediated action potentials in isolated papillary muscle by 83%, did not modify Vmax of slow calcium-mediated action potentials. It prolonged duration of the latter but did not modify that of the former. However, the plateau phase of both the 'fast' and especially the 'slow' action potentials was prolonged. 6. It is concluded that the main electrophysiological effects of a known antifibrillatory dose of Org 7797 in dogs with normal cardiac function are seen at the level of the AV node, actions which are unlikely to be explained by calcium channel block. Higher doses display a class Ic profile. This preferential action on the AV node may contribute to the control of ventricular rate during atrial fibrillation in the absence of infra-nodal conduction disturbances.7. These results contrast with those previously obtained in infarcted dogs and might further suggest that myocardial infarction enhances the Class I action of Org 7797.
Collapse
Affiliation(s)
- J Leboeuf
- Department of Pharmacology, RL. CERM, Riom, France
| | | | | |
Collapse
|
43
|
Mondardini A, Pasquino P, Bernardi P, Aluffi E, Tartaglino B, Mazzucco G, Bonino F, Verme G, Negro F. Propafenone-induced liver injury: report of a case and review of the literature. Gastroenterology 1993; 104:1524-6. [PMID: 8482464 DOI: 10.1016/0016-5085(93)90365-j] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A case of an acute cholestatic syndrome associated with use of the antiarrhythmic drug propafenone is reported here. The close time relationship between the administration of the drug and the acute onset of the liver damage, the histological findings, and the reappearance of biochemical signs of liver dysfunction upon rechallenge with the same medication strongly suggest that propafenone was involved in the pathogenesis of this syndrome. Although rare, hepatotoxicity from this widely used antiarrhythmic medication should be kept in mind in the differential diagnosis of sudden cholestatic syndrome of obscure origin.
Collapse
Affiliation(s)
- A Mondardini
- Department of Gastroenterology, Molinette Hospital, Torino, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Delgado C, Tamargo J, Henzel D, Lorente P. Effects of propafenone on calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 1993; 108:721-7. [PMID: 8385535 PMCID: PMC1908021 DOI: 10.1111/j.1476-5381.1993.tb12868.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
1. The modulation of L-type voltage-sensitive calcium channels in guinea-pig isolated ventricular myocytes by propafenone was examined by the whole cell voltage-clamp technique. 2. Propafenone, 10(-7) -5 x 10(-5) M, produced a concentration-dependent inhibition of Ca current (ICa) without any significant change in the current-voltage relation. Half-blocking concentration (IC50) of propafenone for the peak ICa at +10 mV was 5 x 10(-6) M. 3. The voltage-dependence of ICa inactivation was shifted in the hyperpolarizing direction in the presence of 5 x 10(-6) M propafenone. 4. A frequency-dependent relative block by propafenone was observed after repetitive depolarizing test pulses at a frequency of 0.5 and 1 Hz. The recovery of ICa from inactivation was prolonged by propafenone and the reactivation exhibited an additional exponential component attributed to the slow release from drug block of Ca channels. 5. These results suggest that propafenone, at therapeutic concentrations exhibits Ca channel blocking properties that may be involved in its antiarrhythmic mechanism.
Collapse
Affiliation(s)
- C Delgado
- Institute of Pharmacology and Toxicology (CSIC), School of Medicine, Universidad Complutense, Madrid, Spain
| | | | | | | |
Collapse
|
45
|
Nakamura T, Kashimoto S, Oguchi T, Kumazawa T. Effects of propafenone on function and metabolism in the ischemic working rat heart. Heart Vessels 1992; 7:169-74. [PMID: 1487455 DOI: 10.1007/bf01744601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We examined the effects of propafenone, a new anti-dysrhythmic agent, on myocardial function and metabolism in ischemic working rat heart preparations. In the treated hearts, propafenone, 0.3 micrograms/ml and 3 micrograms/ml, were added to Krebs-Henseleit bicarbonate buffer perfusate throughout the experiments. Whole heart ischemia was induced through a one-way aortic valve for 15 min followed by 'reperfusion for 30 min. After induction of ischemia, the cardiac output, peak aortic systolic pressure, left ventricular dP/dtmax, and myocardial ATP concentration were greater in the treated hearts than in the untreated ones. All hearts in the untreated group developed ventricular fibrillation (Vf) at the beginning of the reperfusion period. On the other hand, no treated hearts had Vf at any time during the experiment. However, propafenone, 3 micrograms/ml, evoked a negative inotropic effect before and after ischemia. These results indicate that propafenone may contribute to early recovery from ischemia in myocardial function and metabolism, although it has a negative inotropic action.
Collapse
Affiliation(s)
- T Nakamura
- Department of Anesthesiology, Yamanashi Medical College, Japan
| | | | | | | |
Collapse
|
46
|
Affiliation(s)
- U Birgersdotter-Green
- Department of Pharmacology, Vanderbilt University, School of Medicine, Nashville, TN 37232
| |
Collapse
|
47
|
Harrison DC, Bottorff MB. Advances in antiarrhythmic drug therapy. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 1992; 23:179-225. [PMID: 1540535 DOI: 10.1016/s1054-3589(08)60966-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- D C Harrison
- University of Cincinnati Medical Center, Ohio 45267
| | | |
Collapse
|
48
|
Puigdemont A, Guitart R, de Mora F, Arboix M. Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other animal species. J Pharm Sci 1991; 80:1106-9. [PMID: 1815066 DOI: 10.1002/jps.2600801203] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Most allometric studies performed until now have considered results obtained by different authors. The parameters mentioned in these studies reflect experiments made under very different conditions and have been calculated by assembling these heterogeneous data reported in the literature. In this paper, we present an allometric study of propafenone carried out in eight animal species, all treated and handled under the same conditions, and taking into account their weight to calculate different pharmacokinetic parameters. Propafenone plasma concentration-time data were analyzed by a model-independent method, and the pharmacokinetic parameters (Y) were correlated with body weight (B) using linear regression analysis by the equation Y = aBx. In addition, human and dog pharmacokinetic parameters were predicted from the results obtained in the other seven species and compared with the experimentally observed values. We demonstrated that these predictions are subject to great error when drugs with extensive metabolism, such as propafenone, are considered.
Collapse
Affiliation(s)
- A Puigdemont
- Department of Pharmacology, School of Veterinary, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | | | | | | |
Collapse
|
49
|
Campbell JK, Marshall RJ, Winslow E. Comparison of the electrophysiological effects of Org 7797, disopyramide, mexiletine and propafenone in anaesthetized dogs with myocardial infarcts. Br J Pharmacol 1991; 104:433-9. [PMID: 1797309 PMCID: PMC1908530 DOI: 10.1111/j.1476-5381.1991.tb12447.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
1. The electrophysiological effects of intravenously administered Org 7797 were compared with those of disopyramide (class Ia), mexiletine (Ib) and propafenone (Ic) in anaesthetized dogs with 5-6 day-old left ventricular myocardial infarcts. 2. Org 7797 (0.5 mg kg-1) slowed conduction at all levels of the myocardium as shown by increases in St-A, AH, HV and QRS intervals, very modestly prolonged atrial and ventricular refractory periods and slightly shortened ventricular repolarization. Sinus node recovery time was increased whilst the RR interval was unchanged. A higher dose (2 mg kg-1) prolonged RR and rendered 5 out of 8 dogs unable to follow an atrial pacing stimulus of mean cycle length 322 ms. 3. Electrophysiological changes induced by propafenone (2 mg kg-1) were qualitatively similar to those of Org 7797 (0.5 mg kg-1). 4. Electrophysiological changes induced by mexiletine (2 mg kg-1) were small or insignificant. The most noticeable effect was a modest increase in the St-A interval and a slight shortening of ventricular repolarization. A higher dose (8 mg kg-1) additionally slowed conduction in the His-Purkinje system and in the ventricular myocardium. 5. Disopyramide (2 and 5 mg kg-1) prolonged all cardiac intervals including JTc, QTc and QT during pacing and prolonged cardiac refractory periods. 6. It was concluded that the electrophysiological profile of Org 7797 is more like that of the Ic agent propafenone than that of the class Ia and Ib drugs, disopyramide and mexiletine.
Collapse
Affiliation(s)
- J K Campbell
- Organon Laboratories Limited, Newhouse, Lanarkshire
| | | | | |
Collapse
|
50
|
Kashimoto S, Oguchi T, Nakamura T, Kumazawa T. Functional and metabolic effects of propafenone in the rat heart-lung preparation. J Anesth 1991; 5:392-5. [PMID: 15278609 DOI: 10.1007/s0054010050392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/1991] [Accepted: 04/30/1991] [Indexed: 10/26/2022]
Abstract
The effects of propafenone on cardiac function and myocardial metabolism were assessed in the isolated rat heart-lung preparation. Propafenone 0.3, 3 or 30 microg.ml(-1) was administered 5 min after the start of perfusion. Heart rate decreased in the 30 microg.ml(-1) group significantly following the drug administration. The highest dose of propafenone (30 microg.ml(-1)) reduced cardiac output significantly, and this dose was associated with a higher incidence of arrhythmias than the other groups. Although there were no significant differences in myocardial lactate and glycogen concentrations among groups, ATP content in the 30 microg.ml(-1) group was significantly less than that in the control group. As therapeutic plasma concentration of propafenone is about 0.6 (range 0.06 to 1.0) microg.ml(-1), 30 microg.ml(-1) is 50 times greater than its concentration. These results suggest that the negative inotropic and chronotropic effects of propafenone are almost same with those of lidocaine which we have previously reported.
Collapse
Affiliation(s)
- S Kashimoto
- Department of Anesthesia, Kohfu City Hospital, Yamanashi, Japan
| | | | | | | |
Collapse
|